Preliminary evidence for gender effects of XXXX monotherapy duration on bone health of @entity1 with @entity302 .

@entity1 @entity4677 @entity29279 @entity170 @entity2331 @entity302
UNASSIGNED: Enzyme-inducing antiepileptic drugs AEDs have adverse effects on bone mineral density (BMD), whereas studies on @entity4677 ( @entity29279 ), a nonenzyme-inducing agent, have showed conflicting results. The aim of this study was to further elucidate the role of @entity29279 in bone health. A sample of forty-six @entity1 with @entity302 (mean age: 35.7years, range: 20.2-64.2years, 39.1% males) on @entity29279 monotherapy for at least one year (range: 1.5-14.5years, median 5.5years) underwent femoral neck (FN) and lumbar spine (LS) BMD measurements. The T- and Z-scores were calculated. Results showed that 15.2% of the @entity1 were identified with @entity2331 and none with @entity170 . Pearson's correlations revealed a negative but not significant association of @entity29279 duration with bone-related measurements (range of rhos: from -0.004 to -0.23), except for LS T-scores. In terms of FN BMD measurements, Z-scores, and T-scores, longer @entity29279 therapy duration had adverse but not significant effects on bone health after adjusting for age and gender. With regard to LS BMD measurements, Z-scores, and T-scores, @entity1 taking @entity29279 for at least 5.5years had better, although not significant, bone health compared with @entity1 with shorter @entity29279 exposure, after adjusting for age. The opposite was found in @entity1 , although differences did not reach significance. These preliminary results are indicative of a differential effect of @entity29279 therapy duration in @entity1 and @entity1 , which could presumably account for the incongruity of the already published studies. Also, LS assessments were more sensitive to these gender differences. Future larger studies should validate these results.
